US Bancorp’s LENZ Therapeutics LENZ Stock Holding History

US Bancorp’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16	Closed	-$146	–	4358
2026 Q1	$146	Buy	+16	New	+$225	﹤0.01%	4118
2025 Q4	–	Sell	-9	Closed	-$419	–	4218
2025 Q3	$419	Buy	+9	New	+$331	﹤0.01%	3885
2025 Q2	–	Sell	-75	Closed	-$1.93K	–	4347
2025 Q1	$1.93K	Sell	75 -41	-35%	-$1.01K	﹤0.01%	3889
2024 Q4	$3.35K	Buy	+116	New	+$3.54K	﹤0.01%	3743

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

US Bancorp's LENZ Position: Q2 2026 in Review

US Bancorp sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 16 shares — an estimated $146 sold.

US Bancorp first reported a position in LENZ in Q4 2024 and held it in 4 quarters. The position peaked at $3.35K in Q4 2024. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

US Bancorp reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
US Bancorp sold 16 LENZ Therapeutics shares in Q2 2026, an estimated $146.
US Bancorp first reported a position in LENZ Therapeutics in Q4 2024 and held it in 4 quarters.
US Bancorp's LENZ Therapeutics position peaked at $3.35K in Q4 2024.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.